SPARCL


Also found in: Medical.
AcronymDefinition
SPARCLStroke Prevention by Aggressive Reduction in Cholesterol Levels
SPARCLSmart Pixel Array Cellular Logic (processor)
SPARCLSonoita Patagonia Alliance for Rural Community Learning
References in periodicals archive ?
The study subjects were ambulatory men and women with no known coronary heart disease who had had ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA) 1-6 months before undergoing randomization in the SPARCL trial.
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, et al, SPARCL Investigators.
An analysis of the SPARCL data was conducted after the study to explore the types of strokes (ischaemic or haemorrhagic) that occurred among patients in the study.
Goldstein LB, Amarenco P, Lamonte M, et al; SPARCL investigators.
In SPARCL, 4,732 patients at high risk for stroke because of a previous stroke or transient ischemic attack were randomized in equal numbers to treatment with atorvastatin or placebo.
The update noted that in conformity with the American Heart Association's guidelines development policy, the guidelines "assume a class effect [for all statins] in the absence of data to the contrary," although the update also noted that it is unclear whether the risk reduction seen in SPARCL was a class effect or was more specific to the regimen of 80 mg/day of atorvastatin.
The update went on to say that in conformity with the American Heart Association's guidelines development policy, the guidelines "assume a class effect [for all statins] in the absence of data to the contrary," although the update also noted that it is currently unclear whether the risk reduction seen in SPARCL was a class effect or was more specific to the regimen of 80 mg/day of atorvastatin.
Pierre Amarenco of Denis Diderot University, Paris, and his associates in the SPARCL trial.
Michael Welch, lead SPARCL investigator, neurologist and president of Rosalind Franklin University of Medicine & Science.
The SPARCL study, published in the New England Journal of Medicine in 2006, is the only study to date evaluating the benefits of a statin solely in patients with a prior stroke or mini-stroke (n=4,731).